While Eisai Inc. is a fully integrated pharmaceutical business capable of discovering, developing, manufacturing, marketing and distributing products on its own, we also recognize the value of collaboration. Eisai believes that its human health care mission of helping to increase the benefits that health care provides to patients and their families can be advanced through collaboration with other companies that share our goal of helping to address unmet medical needs.
Eisai takes a strategic approach to business development activities, ensuring that the expectations of our partners are aligned with our own. We are an experienced and flexible partner that will work diligently to maximize the success of our partners' compounds.
We have a proven track record with a variety of partnerships and collaborations, including strategic copromotions and research collaborations, and we are interested in pursuing opportunities in a variety of therapeutic areas. Eisai offers its partners strong R&D and commercial resources as well as the experience needed to guide products through the regulatory process.
We invite academic institutions and pharmaceutical or biotech companies that share our goal of helping to address unmet medical needs to contact us with proposals.
Eisai has a rich history of partnership that has enabled us to bring innovative new products to the people who need them. We give every product we promote the support and attention it deserves to ensure success in the market place.
From the start, Eisai pioneered "strategic copromotions," or product-focused collaborations without the restrictions of formal joint ventures. Our strategic alliances for Aricept® (donepezil hydrochloride tablets) with Pfizer and AcipHex® (rabeprazole sodium) with Janssen attest to Eisai's ability to discover and develop blockbuster products and to successfully partner with world-class pharmaceutical companies. The launches of these two products, which were discovered and developed by Eisai, are among the most successful in U.S. history, realizing billion-dollar status.
This approach has continued over the years, most recently with Eisai's expanded relationship with Helsinn Healthcare S.A. Building on our successful copromotion relationship for ALOXI® (palonosetron hydrochloride), this arrangement covers the U.S. commercialization of a compound being studied in the area of supportive care.
Eisai has a number of research collaborations with biotech firms and academic institutions. These include agreements with Johns Hopkins University's Brain Science Institute to develop innovative new treatments for central nervous system diseases and Aestus Therapeutics to discover and develop novel therapeutics for the treatment of psychiatric disorders. Most recently, Eisai entered into a broad drug discovery collaboration with FORMA Therapeutics to identify novel oncology drug candidates for otherwise difficult targets.
Our goal with collaborations such as these is to increase our access to external innovation while leveraging synergistic capabilities to support the creation of breakthrough treatments.
We invite you to learn more about Eisai and submit your business opportunity by sending an email to Business Development by clicking here.